Hashimoto’s Thyroiditis: An Overview of Current Evidence from the Literature
DOI:
https://doi.org/10.12775/JEHS.2026.87.68133Keywords
Hashimoto disease, autoimmune thyroiditis, hypothyroidism, thyroid diseaseAbstract
Introduction and purpose
Hashimoto’s thyroiditis is the most prevalent autoimmune disorder of the thyroid and a primary cause of hypothyroidism. It occurs predominantly in women and often manifests with vague, nonspecific complaints, which may also be present in euthyroid patients, leading to delayed recognition. Although levothyroxine remains the cornerstone of therapy, a subset of patients continues to report ongoing symptoms. This review outlines current evidence regarding the epidemiology, pathophysiology, clinical presentation, diagnostic approach, and both established and emerging therapeutic options for this condition.
A brief description of the state of knowledge
Hashimoto’s thyroiditis is a frequent autoimmune disease and the leading cause of hypothyroidism in many populations. Its pathogenesis involves an interplay of genetic predisposition, environmental factors, and dysregulation of the immune response. Clinical manifestations are heterogeneous and may include fatigue, depressive symptoms, and cognitive difficulties, even in the presence of normal thyroid hormone levels. Diagnosis is based on clinical evaluation supported by laboratory assessment of thyroid hormones and antibodies, as well as ultrasound imaging. While levothyroxine effectively normalizes biochemical parameters in most cases, persistent symptoms are commonly reported. This has led to growing interest in adjunctive interventions such as selenium, vitamin D, and inositol supplementation, acupuncture, and lifestyle modification. Increasing attention is also being paid to the influence of the gut–thyroid axis, including the potential role of probiotics in immune modulation. An individualized and more comprehensive treatment strategy may benefit patients with an incomplete response to standard therapy.
Conclusions
Hashimoto’s thyroiditis is a multifactorial autoimmune condition that often necessitates an individualized therapeutic approach. Persistent symptoms despite appropriate treatment are common. Integrating conventional management with supportive measures may enhance clinical outcomes and improve patients’ quality of life.
References
1. Wrońska K, Hałasa M, Szczuko M. The Role of the Immune System in the Course of Hashimoto’s Thyroiditis: The Current State of Knowledge. IJMS. 2024;25(13):6883. doi:10.3390/ijms25136883
2. Ajjan RA, Weetman AP. The Pathogenesis of Hashimoto’s Thyroiditis: Further Developments in our Understanding. Horm Metab Res. 2015;47(10):702-710. doi:10.1055/s-0035-1548832
3. Kust D, Matesa N. The impact of familial predisposition on the development of Hashimoto’s thyroiditis. Acta Clinica Belgica. 2020;75(2):104-108. doi:10.1080/17843286.2018.1555115
4. Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid®. 2024;34(3):295-313. doi:10.1089/thy.2023.0556
5. Chen S, Peng Y, Zhang H, Zou Y. Relationship between thyroid function and dietary inflammatory index in Hashimoto thyroiditis patients. Medicine. 2023;102(46):e35951. doi:10.1097/MD.0000000000035951
6. Jin B, Wang S, Fan Z. Pathogenesis Markers of Hashimoto’s Disease—A Mini Review. Front Biosci (Landmark Ed). 2022;27(10):297. doi:10.31083/j.fbl2710297
7. Rotondi M, Capelli V, Locantore P, Pontecorvi A, Chiovato L. Painful Hashimoto’s thyroiditis: myth or reality? J Endocrinol Invest. 2017;40(8):815-818. doi:10.1007/s40618-017-0655-5
8. Vargas-Uricoechea H. Molecular Mechanisms in Autoimmune Thyroid Disease. Cells. 2023;12(6):918. doi:10.3390/cells12060918
9. Zhu X, Zhang C, Feng S, He R, Zhang S. Intestinal microbiota regulates the gut-thyroid axis: the new dawn of improving Hashimoto thyroiditis. Clin Exp Med. 2024;24(1):39. doi:10.1007/s10238-024-01304-4
10. Qiu K, Li K, Zeng T, et al. Integrative Analyses of Genes Associated with Hashimoto’s Thyroiditis. Duan L, ed. Journal of Immunology Research. 2021;2021:1-9. doi:10.1155/2021/8263829
11. Jabrocka-Hybel A, Skalniak A, Piątkowski J, et al. How much of the predisposition to Hashimoto’s thyroiditis can be explained based on previously reported associations? J Endocrinol Invest. 2018;41(12):1409-1416. doi:10.1007/s40618-018-0910-4
12. Ragusa F, Fallahi P, Elia G, et al. Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Practice & Research Clinical Endocrinology & Metabolism. 2019;33(6):101367. doi:10.1016/j.beem.2019.101367
13. Bothra N, Shah N, Goroshi M, et al. Hashimoto’s thyroiditis: relative recurrence risk ratio and implications for screening of first‐degree relatives. Clinical Endocrinology. 2017;87(2):201-206. doi:10.1111/cen.13323
14. Ralli M, Angeletti D, Fiore M, et al. Hashimoto’s thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmunity Reviews. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649
15. Xu J, Ding K, Mu L, et al. Hashimoto’s Thyroiditis: A “Double-Edged Sword” in Thyroid Carcinoma. Front Endocrinol. 2022;13:801925. doi:10.3389/fendo.2022.801925
16. Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment. Polish Archives of Internal Medicine. Published online March 3, 2022. doi:10.20452/pamw.16222
17. Virili C, Fallahi P, Antonelli A, Benvenga S, Centanni M. Gut microbiota and Hashimoto’s thyroiditis. Rev Endocr Metab Disord. 2018;19(4):293-300. doi:10.1007/s11154-018-9467-y
18. Hu X, Chen Y, Shen Y, Tian R, Sheng Y, Que H. Global prevalence and epidemiological trends of Hashimoto’s thyroiditis in adults: A systematic review and meta-analysis. Front Public Health. 2022;10:1020709. doi:10.3389/fpubh.2022.1020709
19. Bozdag A, Gundogan Bozdag P. Evaluation of systemic inflammation markers in patients with Hashimoto’s thyroiditis. J Int Med Res. 2024;52(9):03000605241280049. doi:10.1177/03000605241280049
20. Peng B, Wang W, Gu Q, Wang P, Teng W, Shan Z. Effects of different supplements on Hashimoto’s thyroiditis: a systematic review and network meta-analysis. Front Endocrinol. 2024;15:1445878. doi:10.3389/fendo.2024.1445878
21. Wang X, Li Y, Xie H, et al. Effect of acupuncture on Hashimoto thyroiditis: A systematic review and meta-analysis. Medicine. 2024;103(9):e37326. doi:10.1097/MD.0000000000037326
22. Cayres LCDF, De Salis LVV, Rodrigues GSP, et al. Detection of Alterations in the Gut Microbiota and Intestinal Permeability in Patients With Hashimoto Thyroiditis. Front Immunol. 2021;12:579140. doi:10.3389/fimmu.2021.579140
23. Hu X, Wang X, Liang Y, et al. Cancer Risk in Hashimoto’s Thyroiditis: a Systematic Review and Meta-Analysis. Front Endocrinol. 2022;13:937871. doi:10.3389/fendo.2022.937871
24. Chahardoli R, Saboor-Yaraghi AA, Amouzegar A, Khalili D, Vakili A, Azizi F. Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto’s Thyroiditis? A Double Blind, Randomized Clinical Trial. Horm Metab Res. 2019;51(05):296-301. doi:10.1055/a-0856-1044
25. Tywanek E, Michalak A, Świrska J, Zwolak A. Autoimmunity, New Potential Biomarkers and the Thyroid Gland—The Perspective of Hashimoto’s Thyroiditis and Its Treatment. IJMS. 2024;25(9):4703. doi:10.3390/ijms25094703
26. Gong B, Wang C, Meng F, et al. Association Between Gut Microbiota and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis. Front Endocrinol. 2021;12:774362. doi:10.3389/fendo.2021.774362
27. Zhang Q, Lan X. Assessment of causal association between autoimmune thyroiditis and thyroid cancer: A Mendelian randomization study. Medicine. 2025;104(9):e41633. doi:10.1097/MD.0000000000041633
28. Kenarlı K, Bahçecioğlu AB, Aksu ÖB, Güllü S. Are sonographic characteristics of Hashimoto’s thyroiditis related with immunologic parameters? A cross-sectional study. J Endocrinol Invest. 2024;47(7):1701-1709. doi:10.1007/s40618-023-02286-y
29. Liu J, Qin X, Lin B, et al. Analysis of gut microbiota diversity in Hashimoto’s thyroiditis patients. BMC Microbiol. 2022;22(1):318. doi:10.1186/s12866-022-02739-z
30. Weetman AP. An update on the pathogenesis of Hashimoto’s thyroiditis. J Endocrinol Invest. 2021;44(5):883-890. doi:10.1007/s40618-020-01477-1
31. Dove AE, Marathe PH, Gao HX, Close KL. American Association of Clinical Endocrinologists 2017. Journal of Diabetes. 2017;9(9):817-820. doi:10.1111/1753-0407.12573
32. Wang S, Zhao J, Zeng W, et al. Acupuncture for Hashimoto thyroiditis: study protocol for a randomized controlled trial. Trials. 2021;22(1):74. doi:10.1186/s13063-021-05036-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Dworak, Marta Kowalska, Anna Mazur, Julia Brodziak, Wiktor Werenkowicz, Wiktoria Ciszewska, Zofia Kosztyła-Czech, Tomasz Wiśniewski, Mateusz Matyja

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 10
Number of citations: 0